BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – SunTrust Banks issued their Q1 2018 earnings estimates for BioMarin Pharmaceutical in a research report issued on Monday. SunTrust Banks analyst E. Nash forecasts that the biotechnology company will post earnings of ($0.17) per share for the quarter. SunTrust Banks has a “Buy” rating and a $115.00 price objective on the stock. SunTrust Banks also issued estimates for BioMarin Pharmaceutical’s Q2 2018 earnings at ($0.12) EPS and Q4 2018 earnings at ($0.06) EPS.

BMRN has been the topic of several other reports. Morgan Stanley reiterated an “overweight” rating and issued a $117.00 price target (up from $115.00) on shares of BioMarin Pharmaceutical in a research report on Friday, October 6th. Stifel Nicolaus lowered their price target on shares of BioMarin Pharmaceutical from $107.00 to $105.00 and set a “buy” rating on the stock in a research report on Friday. BMO Capital Markets reiterated a “buy” rating and issued a $117.00 price target on shares of BioMarin Pharmaceutical in a research report on Friday, October 20th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and issued a $129.00 price target on shares of BioMarin Pharmaceutical in a research report on Friday, October 6th. Finally, J P Morgan Chase & Co set a $130.00 price target on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research report on Sunday. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and sixteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $111.55.

TRADEMARK VIOLATION NOTICE: “Q1 2018 Earnings Estimate for BioMarin Pharmaceutical Inc. Issued By SunTrust Banks (BMRN)” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/31/q1-2018-earnings-estimate-for-biomarin-pharmaceutical-inc-issued-by-suntrust-banks-bmrn.html.

BioMarin Pharmaceutical (NASDAQ BMRN) traded down 0.5337% on Tuesday, reaching $81.5325. 521,412 shares of the company’s stock were exchanged. The company’s market cap is $14.29 billion. BioMarin Pharmaceutical has a 12-month low of $78.42 and a 12-month high of $100.51. The firm has a 50 day moving average of $91.43 and a 200-day moving average of $89.94.

BioMarin Pharmaceutical (NASDAQ:BMRN) last released its earnings results on Thursday, October 26th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.06. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.61%. The business had revenue of $334.18 million for the quarter, compared to analyst estimates of $347.38 million. During the same period last year, the company posted $0.02 EPS. The business’s revenue was up 19.4% on a year-over-year basis.

Hedge funds have recently modified their holdings of the company. Swiss National Bank raised its stake in shares of BioMarin Pharmaceutical by 3.6% in the 2nd quarter. Swiss National Bank now owns 631,600 shares of the biotechnology company’s stock valued at $57,362,000 after acquiring an additional 22,200 shares during the period. Aperio Group LLC raised its stake in shares of BioMarin Pharmaceutical by 9.7% in the 2nd quarter. Aperio Group LLC now owns 56,491 shares of the biotechnology company’s stock valued at $5,131,000 after acquiring an additional 5,006 shares during the period. Prudential Financial Inc. raised its stake in shares of BioMarin Pharmaceutical by 2.9% in the 2nd quarter. Prudential Financial Inc. now owns 145,170 shares of the biotechnology company’s stock valued at $13,185,000 after acquiring an additional 4,026 shares during the period. Eagle Asset Management Inc. raised its stake in shares of BioMarin Pharmaceutical by 21.7% in the 2nd quarter. Eagle Asset Management Inc. now owns 306,353 shares of the biotechnology company’s stock valued at $27,822,000 after acquiring an additional 54,675 shares during the period. Finally, Comgest Global Investors S.A.S. raised its stake in shares of BioMarin Pharmaceutical by 49.1% in the 2nd quarter. Comgest Global Investors S.A.S. now owns 24,000 shares of the biotechnology company’s stock valued at $2,180,000 after acquiring an additional 7,900 shares during the period. 97.58% of the stock is currently owned by institutional investors and hedge funds.

In other news, insider Henry J. Fuchs sold 15,000 shares of the firm’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $90.50, for a total value of $1,357,500.00. Following the transaction, the insider now owns 141,422 shares of the company’s stock, valued at approximately $12,798,691. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Robert Baffi sold 18,415 shares of the firm’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $92.43, for a total transaction of $1,702,098.45. Following the completion of the transaction, the executive vice president now directly owns 129,083 shares in the company, valued at approximately $11,931,141.69. The disclosure for this sale can be found here. In the last three months, insiders sold 40,686 shares of company stock worth $3,736,318. Insiders own 1.85% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.